Mental Health & Psychiatry Clinical Trials Update: Week 24, 2026

Published June 12, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Folinic Acid as a Treatment for Autism Spectrum Disorder in Children

This Phase 2 trial is exploring whether folinic acid can help improve communication and behavior in children with autism spectrum disorder. Recruiting in Singapore, it offers hope for families seeking new treatment options that do not require prior therapies. If successful, this study could provide a simple supplement-based approach to support children’s development and daily functioning.

Study on Mental Health Promoting Effects of Natural Psychotherapy for Adolescents

This study is testing a natural psychotherapy program designed to reduce anxiety and depression among adolescents. The trial plans to enroll 3,000 students in China and will follow them for six months after the intervention. This research could lead to widely accessible, non-drug options to support young people’s mental well-being during a critical time of growth.

Imaging SV2A in Mood Disorders

Researchers at Yale University are investigating how ketamine affects brain synaptic density in people with major depressive disorder and post-traumatic stress disorder. By using brain imaging techniques like MRI and PET scans, this study aims to better understand how ketamine may improve symptoms by targeting brain changes directly. This could eventually help tailor treatments for those living with mood disorders.

Experimental Evidence of the Impact of Parental Income on Child Mental Health and Neuroimmune Function

This study examines how income supplements for lower-income families influence mental health and brain immune function in children aged 5 to 14. Recruiting in the United States, it seeks to understand whether reducing financial stress can support better mental health and brain development. The findings may inform policies aimed at improving the well-being of children living in poverty.

Cannabidiol and Older Adult Cannabis Users

This Phase 2 trial is testing cannabidiol (CBD) as a treatment for sleep problems, anxiety, depression, and pain in adults aged 65 and older. Recruiting in the United States, the study evaluates whether CBD offers a safer alternative to traditional medications for these common issues. Positive results could expand options for managing symptoms in older adults using cannabis-derived products.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.